August 14, 2024
Sponsored by Thermo Fisher Scientific
This white paper explores the challenges of in-house buffer and process liquid preparation in bioprocessing operations, including operational inefficiencies, contamination risks, and costly batch failures. These challenges can result in production delays and increased operational costs.
Key Challenges Addressed:
Operational Inefficiencies: Discover the hidden costs and delays associated with in-house buffer preparation that could be slowing down your production timelines.
Contamination Risks: Understand the contamination hazards that threaten your batch integrity and learn how to minimize these risks.
Financial Burdens: Uncover the financial strain of maintaining extensive warehouse space, equipment, and specialized personnel, and how these factors contribute to your overall cost burden.
Discover how a clinical-stage biotherapeutics company successfully addressed scaling challenges in immunotherapy development by outsourcing their buffer manufacturing. By partnering with a trusted expert, they avoided major capital expenditures, reduced lead times, and enhanced overall productivity.
Learning Outcomes:
Streamlined Operations: Learn how outsourcing buffer preparation can eliminate bottlenecks in your process, freeing up valuable resources and reducing production time.
Cost Savings: Discover the potential for substantial savings in both capital and operational expenditures, allowing you to reinvest in critical areas of your business.
Enhanced Quality and Reliability: See how working with experienced partners can improve order accuracy, ensure quality standards, and mitigate the risks of supply chain disruptions.
This white paper is an essential read for biomanufacturers looking to optimize their operations, reduce costs, and focus on what matters most—bringing life-changing therapies to market faster and more efficiently.
You May Also Like
